A study involving ovarian cancer patients treated with carboplatin showed that one out of 60 patients (1.7%) harbored a BRCA1/2 mutation that restored ORF in one cohort of patients, while in another cohort, the incidence of such mutations was 46.2% in patients who had platinum-resistant disease, significantly higher when compared to 5.3% in patients with platinum-sensitive disease (p = 0.003) [34]. This evidence concerns the gene BRCA1 and ovarian carcinoma.